🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Moderately to Severely Active Ulcerative Colitis

Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis NCT06453317Phase 21 site📍 Lodz Medical University of Lodz · Tests: Infliximab, Ustekinumab A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis NCT07470879Phase 246 sites📍 Indianapolis📍 Indianapolis📍 Indianapolis Pfizer · Tests: Etrasimod Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis NCT07136116n/a29 sites📍 Nagakute📍 Nagoya📍 Hirosaki AbbVie A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea NCT06073873n/a1 site📍 Seoul Bristol-Myers Squibb · Tests: Ozanimod A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis NCT07846683Phase 31 site📍 Cordova Hoffmann-La Roche · Tests: Afimkibart, Placebo A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) NCT06764615Phase 216 sites📍 Glen Burnie📍 Tyler📍 Chongqing Takeda · Tests: Zasocitinib A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) NCT07463183Phase 239 sites📍 Anaheim📍 Coronado📍 Colorado Springs Merck Sharp & Dohme LLC · Tests: MK-8690, Placebo A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis NCT07374471Phase 1, Phase 27 sites📍 Tbilisi📍 Chisinau📍 Katowice Mage Biologics · Tests: MB-001, Matching placebo to MB-001 The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC NCT07507513Phase 21 site📍 Guangzhou Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: 627, Placebo A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis NCT05287126Phase 247 sites📍 Little Rock📍 Little Rock📍 Garden Grove Pfizer · Tests: Etrasimod A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting NCT06581328Phase 4101 sites📍 Birmingham📍 Mobile📍 Chandler Takeda · Tests: Vedolizumab IV, Vedolizumab SC Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis NCT06764706n/a57 sites📍 Heidelberg📍 Potsdam📍 Wriezen AbbVie A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis NCT06865417Phase 346 sites📍 Brussels📍 Liège📍 Namur Alfasigma S.p.A. · Tests: Filgotinib An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis NCT07665723Phase 118 sites📍 Chula Vista📍 Miami📍 Miami Hoffmann-La Roche · Tests: Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis NCT07697456Phase 266 sites📍 Dothan📍 Phoenix📍 Sun City AbbVie · Tests: Risankizumab, Trosunilimab, ABBV-701 A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis NCT07196748Phase 3402 sites📍 Chandler📍 Litchfield Park📍 Scottsdale Janssen Research & Development, LLC · Tests: Icotrokinra, Placebo Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis NCT07686081Phase 32 sites📍 Chula Vista📍 Nashville Vanda Pharmaceuticals · Tests: Ponesimod, Placebo An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) NCT06838845n/a3 sites📍 Guangzhou📍 Guangzhou📍 Zhengzhou AbbVie Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis NCT06850727Phase 232 sites📍 Birtinya📍 Box Hill📍 Maroochydore Odyssey Therapeutics, Inc. · Tests: OD-07656, Vedolizumab A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis NCT07158242Phase 326 sites📍 Aurora📍 Hartford📍 Tampa Hoffmann-La Roche · Tests: Afimkibart A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis NCT07577856Phase 3279 sites📍 Anaheim📍 Chula Vista📍 Los Alamitos Janssen Research & Development, LLC · Tests: JNJ-78934804, Guselkumab A Study for HSK47388 in Participants With Ulcerative Colitis NCT07335055Phase 21 site📍 Hangzhou Haisco Pharmaceutical Group Co., Ltd. · Tests: HSK47388, Placebo A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis NCT07185009Phase 3171 sites📍 Tucson📍 Coronado📍 Murrieta Sanofi · Tests: Duvakitug, Placebo Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease NCT06754891Phase 130 sites📍 Bengbu📍 Wuwei📍 Guangzhou Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: 24mg bid TQH3906 capsule, 32mg TQH3906 capsule, TQH3906 placebo A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis NCT07845487Phase 2115 sites📍 Sun City📍 San Diego📍 Bristol Palisade Bio · Tests: PALI-2108, PALI-2108, Placebo A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis NCT05076175Phase 2, Phase 391 sites📍 Phoenix📍 Tucson📍 Garden Grove Bristol-Myers Squibb · Tests: Ozanimod An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis NCT07184996Phase 3240 sites📍 Peoria📍 Scottsdale📍 Scottsdale Sanofi · Tests: Duvakitug, Placebo Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC) NCT07513181Phase 24 sites📍 Miami📍 Tampa📍 Roswell Athos Therapeutics Inc · Tests: ATH-063, Placebo Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis NCT07080034Phase 220 sites📍 Barnaul📍 Ufa📍 Rostov-on-Don Biocad · Tests: anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, hig… Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis NCT06619990Phase 1, Phase 2114 sites📍 Scottsdale📍 Palo Alto📍 Bradenton Xencor, Inc. · Tests: XmAb942, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy